atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
The UK Government’s announcement to be an AI superpower will impact every L&D professional’s future.
The UK government announced it’s AI Opportunities Action Plan, which has three key goals:
To lay the foundations for AI
To change lives by embracing AI
To secure the…
Tom Jackson highlights a recent report demonstrating how organisations can incorporate AI within their learning and development practices.
Organisations are using AI solutions to quickly craft tailored learning experiences for each team member and/or team need, making the learning process…
Attendees
Sponsors and
Exhibitors
AI Training
for Doctors Workshops
Contact us